Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 80Lymphoid 11Sarcoma 7Other hematologic neoplasm 4Thoracic 2Dermatologic 2Plasma cell 1Other solid neoplasm 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 870Lenalidomide 456Bortezomib 454Cyclophosphamide 365Melphalan 271Calcium Dobesilate 262daratumumab 233pomalidomide 207carfilzomib 182fludarabine phosphate 140fludarabine 136Thalidomide 125Peripheral Blood Stem Cell Transplantation 119Filgrastim 114ixazomib 93Mycophenolic Acid 90Granulocyte Colony-Stimulating Factor 89Whole-Body Irradiation 87Busulfan 87dexamethasone acetate 86Tacrolimus 78dexamethasone 21-phosphate 74Cyclosporine 68isatuximab 67auricularum 67Prednisone 65elotuzumab 58belantamab mafodotin 56Antilymphocyte Serum 56Etoposide 53

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Lomustine × Plasma cell × Clear all
NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
660 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡